dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Prager, Gerald W |
dc.contributor.author | Westphalen, C Benedikt |
dc.contributor.author | D'Esquermes, Nathalie |
dc.contributor.author | Ferreras, Anabel |
dc.contributor.author | Macarulla Mercadé, Teresa |
dc.contributor.author | Taieb, Julien |
dc.contributor.author | Melisi, Davide |
dc.date.accessioned | 2021-10-22T05:44:42Z |
dc.date.available | 2021-10-22T05:44:42Z |
dc.date.issued | 2020-01-20 |
dc.identifier.citation | Taieb J, Prager GW, Melisi D, Westphalen CB, D’Esquermes N, Ferreras A, et al. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. ESMO Open. 2020 Jan 20;5:e000587. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/6435 |
dc.description | Europa occidental; Gemcitabina; Càncer de pàncrees |
dc.description.sponsorship | The study was funded by Shire (Zug, Switzerland). Medical writing assistance was initially funded by Shire and subsequently by Servier Global Medical Affairs (Suresnes, France). Although employees of the sponsor were involved in the design, collection, analysis, interpretation, fact checking of information, and coordination and collation of comments, the content of this manuscript, the interpretation of the data and the decision to submit the manuscript for publication in ESMO Open were made by the authors independently. |
dc.language.iso | eng |
dc.publisher | BMJ |
dc.relation.ispartofseries | ESMO Open;5 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Pàncrees - Càncer - Quimioteràpia |
dc.subject | Adenocarcinoma - Quimioteràpia |
dc.subject.mesh | Pancreatic Neoplasms |
dc.subject.mesh | Adenocarcinoma |
dc.subject.mesh | /drug therapy |
dc.title | First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1136/esmoopen-2019-000587 |
dc.subject.decs | neoplasias pancreáticas |
dc.subject.decs | adenocarcinoma |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.1136/esmoopen-2019-000587 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Taieb J] Hôpital Européen Georges Pompidou, AP-HP, Paris, France. Sorbonne Paris Cité, Université Paris Descartes, Paris, France. [Prager GW] Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria. [Melisi D] Digestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli Studi di Verona, Verona, Veneto, Italy. [Westphalen CB] Department of Medicine III and Comprehensive Cancer Center Munich, University Hospital LMU Munich, Munich, Germany. [D'Esquermes N, Ferreras A] Genactis SAS, Mougins, France. [Macarulla T] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 31958291 |
dc.identifier.wos | 000527764500006 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |